GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Direct targeting of mutant KRas is challenging and alternative approaches are needed. Here they show glycogen synthase kinase 3 (GSK3) to be required for the growth and survival of human mutant KRas-dependent tumors but dispensable for mutant KRas-independent tumors and show GSK3 inhibition to inhib...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Aslamuzzaman Kazi, Shengyan Xiang, Hua Yang, Daniel Delitto, José Trevino, Rays H. Y. Jiang, Muhammad Ayaz, Harshani R. Lawrence, Perry Kennedy, Saïd M. Sebti
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Q
Acceso en línea:https://doaj.org/article/e4dd4e549d124d48b1ca42f85db738ff
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!